FDA Approves Direct-to-Consumer Test for BRCA Mutations

Share this content:
As the report covers only 3 of 1000 known BRCA variants, a negative result does not mean an individual is at a lower cancer risk.
As the report covers only 3 of 1000 known BRCA variants, a negative result does not mean an individual is at a lower cancer risk.

The US Food and Drug Administration (FDA) approved a direct-to-consumer test for 3 BRCA mutations, according to a press release.1 The covered mutations are, however, the most common only among individuals of Ashkenazi Jewish descent, rather than the general population.

The approval is for the Personal Genome Service Genetic Health Risk (GHR) Report, which tests for particular variants of BRCA1/2, and may help to determine a woman's risk of breast and ovarian cancer and a man's risk of prostate cancer. The GHR report analyzes data from an individual's saliva sample.

As the report covers only 3 of 1000 known BRCA variants, a negative result does not mean an individual is at a lower cancer risk.

While these variants are found in about 2% of Ashkenazi women, they are present in up to only 0.1% of individuals in other ethnic groups.

The press release notes, furthermore, that consumers and health care professionals should not use this test's results to determine any treatments.

The GHR report was developed by 23andMe. More information can be found here.

Reference

  1. FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes [news release]. Silver Spring, MD: US Food and Drug Administration; March 6, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599560.htm?utm_campaign=03062018_PR_23andme_BRCA. Accessed March 7, 2018.

The US Food and Drug Administration (FDA) approved a direct-to-consumer test for 3 BRCA mutations, according to a press release.1 The covered mutations are, however, the most common only among individuals of Ashkenazi Jewish descent, rather than the general population.

 

The approval is for the Personal Genome Service Genetic Health Risk (GHR) Report, which tests for particular variants of BRCA1/2, and may help to determine a woman's risk of breast and ovarian cancer and a man's risk of prostate cancer. The GHR report analyzes data from an individual's saliva sample.

 

As the report covers only 3 of 1000 known BRCA variants, a negative result does not mean an individual is at a lower cancer risk.

 

While these variants are found in about 2% of Ashkenazi women, they are present in up to only 0.1% of individuals in other ethnic groups.

 

The press release notes, furthermore, that consumers and health care professionals should not use this test's results to determine any treatments.

 

The GHR report was developed by 23andMe. More information can be found here.

 

Reference

 

1.     FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes [news release]. Silver Spring, MD: US Food and Drug Administration; March 6, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599560.htm?utm_campaign=03062018_PR_23andme_BRCA. Accessed March 7, 201

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs